|Epigenomics AG -- USA Stock|| |
USD 4.55 0.12 2.71%
CEO of Epigenomics Inc.
Mr. Noel Doheny was Chief Executive Officer of Epigenomics Inc. of Epigenomics AG since May 2011. He has 30 years of experience in the field of diagnostics, with over 20 years in senior management. Prior to joining Epigenomics, he held positions as CEO of OpGen, Senior Vice President for the Molecular Diagnostics Division of Affymetrix Inc., Vice President of PreAnalytical Solutions and a member of the Executive Committee at QIAGEN as well as President and CEO of BioStar Inc. He has built several operating teams from the ground up, including the commercial teams to launch novel products at companies such as Ciba Corning, Biostar, and OpGen. Noel obtained degrees in Biology and Chemistry from West Virginia University and attended Georgetown University for postgraduate studies in Biochemistry prior to moving into industry.
CEO Since 2011
49 30 243 450 http://www.epigenomics.com
The company has return on total asset (ROA)
of (44.29) %
which means that it has lost $44.29 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (122.69) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 607.04 K in total debt with debt to equity ratio (D/E) of 5.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Epigenomics AG has Current Ratio of 1.92 which is within standard range for the sector.
Epigenomics AG, a molecular diagnostics company, focuses on developing and commercializing in vitro diagnostic tests for the screening, early detection, and diagnosis of cancer in Germany and internationally. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany. Epigenomics AG is traded on OTC Market in USA.Epigenomics AG (EPGNF) is traded on OTC Market in USA. It is located in Geneststrasse 5 and employs 43 people.
Epigenomics AG Leadership Team
|Antje Zeise, Executive|
|Guenther Reiter, Executive|
|Gregory Hamilton, CEO, MBA|
|Ann Kessler, Executive|
|Heino Prondzynski, Chairman|
|Helge Lubenow, Executive, Ph.D|
|Thomas Taapken, CEO|
|Annett Dietrich, Executive|
|Noel Doheny, CEO|
|Uwe Staub, COO, Ph.D|
|Albert Weber, SVP|
|Nicola HennebergBusse, President|
|Jorge Garces, President, MBA|
|Nicholas Potter, Director|
|Peter Vogt, Executive|
Stock Performance Indicators
Macroaxis portfolio users are insensible in their opinion about investing in Epigenomics AG. What is your opinion about investing in Epigenomics AG? Are you bullish or bearish?
The main assumption in equity investing is that a higher degree of volatility (or risk) means a higher potential (or expected) return on investment. Conversely, investors who take on a low degree of risk have a low expection for return.
You can create optimal portfolios in USA market or optimize your existing portfolio in one of two ways: 1)
For any level of risk, select the one which has the highest expected return. 2)
For any expected return, select the one which has the lowest volatility.